• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by National Research Corporation (Amendment)

    1/4/24 5:05:08 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $NRC alert in real time by email
    SC 13D/A 1 schedule13da.htm SCHEDULE 13D/A


    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13D/A
    (Rule 13d-101)

    Under the Securities Exchange Act of 1934
    (Amendment No. 8)

    National Research Corporation
    __________________________________________________________________________________
    (Name of Issuer)

    Common Stock, $.001 par value
    __________________________________________________________________________________
    (Title of Class of Securities)

    637372202
    __________________________________________________________________________________
    (CUSIP Number)

    Patrick E. Beans
    Amandla LLC
    709 Pier 2
    Lincoln, NE 68528
    402-440-2768
    __________________________________________________________________________________
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    January 2, 2024
    __________________________________________________________________________________
    (Date of Event Which Requires Filing of this Statement)
     
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [  ]
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).
     

    CUSIP NO.:  637372202

    1.
    Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
     
    Patrick E. Beans, as the Special Holdings Direction Adviser under the Amandla MK Trust
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) [   ]
    (b) [   ]
    3.
    SEC USE ONLY
     
    4.
    Source of Funds (See Instructions)
    OO
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
    [   ]
    6.
    Citizenship or Place of Organization
     
    United States of America
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person with
    7.
    Sole Voting Power
    4,762,531
     
    8.
    Shared Voting Power
    0
     
     
    9.
    Sole Dispositive Power
    4,762,531
     
     
    10.
    Shared Dispositive Power
    0
     
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
    4,762,531
     
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
    [    ]
    13.
    Percent of Class Represented by Amount in Row (11)
    19.4%(1)
     
    14.
    Type of Reporting Person (See Instructions)
    IN
     

     
    (1)
    The percentage indicated is based upon 24,558,330 shares of common stock outstanding as of November 3, 2023, as reported in the Issuer's Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 9, 2023.

    CUSIP NO.:  637372202

    1.
    Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
     
    Amandla MK Trust
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) [   ]
    (b) [   ]
    3.
    SEC USE ONLY
     
    4.
    Source of Funds (See Instructions)
    OO
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
    [   ]
    6.
    Citizenship or Place of Organization
     
    Delaware
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person with
    7.
    Sole Voting Power
    4,762,531
     
    8.
    Shared Voting Power
    0
     
     
    9.
    Sole Dispositive Power
    4,762,531
     
     
    10.
    Shared Dispositive Power
    0
     
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
    4,762,531
     
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
    [    ]
    13.
    Percent of Class Represented by Amount in Row (11)
    19.4%(1)
     
    14.
    Type of Reporting Person (See Instructions)
    OO
     

     
    (1)
    The percentage indicated is based upon 24,558,330 shares of common stock outstanding as of November 3, 2023, as reported in the Issuer's Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 9, 2023.

    CUSIP NO.:  637372202

    Item 1.
    Security and Issuer.

    This Amendment No. 8 to Schedule 13D, which relates to shares of the Common Stock, par value $.001 per share (the “Common Stock”), of National Research Corporation, a Delaware corporation (the “Issuer”), is being filed on behalf of Patrick E. Beans, as Special Holdings Direction Adviser under the Amandla MK Trust (the “Adviser”), and the Amandla MK Trust (the “Trust”) to amend the Reporting Persons’ Schedule 13D, as amended (the “Schedule 13D”), originally filed on February 2, 2018.  Unless otherwise indicated, all capitalized terms used herein but not defined herein shall have the same meanings as set for in the Schedule 13D.  The address of the principal executive offices of the Issuer is 1245 Q Street, Lincoln, Nebraska 68508.

    Item 5.
    Interest in Securities of the Issuer.

    Item 5 of the Schedule 13D is hereby amended and supplemented by adding the following information:

    (a) Set forth below is the aggregate number and percentage of outstanding shares of Common Stock owned beneficially by each Reporting Person named in Item 2 (based on 24,558,330 shares of Common Stock outstanding as of November 3, 2023):

    Name
    Shares of Common Stock
    Beneficially Owned
    Percentage of Shares of Common Stock Beneficially Owned
    Trust and Adviser
    Common Stock –4,762,531
    19.4%

    The Adviser is the Special Holdings Direction Adviser under the Trust and may be deemed to have sole voting and dispositive power with regard to the shares of Common Stock held by the Trust.  The shares beneficially owned by the Trust are held directly by Amandla II LLC, which is 100% owned by the Trust, and Amandla LLC, which is 100% owned by Amandla II LLC.

    (c) The following transactions in the Common Stock have occurred during the past 60 days by the Reporting Persons:

    Name
    Trade Date
    Number of Shares Sold
    Weighted Average Price Per Share
    Where and How Transaction was Effected
    Range of Prices per Share
    Trust and Adviser
    11/15/2023
    403
    $42.1037
    Open market sale
    $42.10 to $42.115
    Trust and Adviser
    11/20/2023
    57
    $42.10
    Open market sale
    $42.10
    Trust and Adviser
    11/21/2023
    100
    $42.05
    Open market sale
    $42.05
    Trust and Adviser
    11/22/2023
    627
    $42.0766
    Open market sale
    $42.05 to $42.20
    Trust and Adviser
    12/04/2023
    100
    $41.60
    Open market sale
    $41.60
    Trust and Adviser
    12/05/2023
    1,498
    $41.60
    Open market sale
    $41.60
    Trust and Adviser
    12/06/2023
    952
    $41.60
    Open market sale
    $41.60
    Trust and Adviser
    12/07/2023
    4,738
    $41.5641
    Open market sale
    $41.55 to $41.58
    Trust and Adviser
    12/08/2023
    12,328
    $41.55
    Open market sale
    $41.55
    Trust and Adviser
    12/11/2023
    37,638
    $41.5550
    Open market sale
    $41.55 to $41.61
    Trust and Adviser
    12/12/2023
    21,884
    $41.5501
    Open market sale
    $41.55 to $41.56
    Trust and Adviser
    12/13/2023
    3,779
    $41.5526
    Open market sale
    $41.55 to $41.565
    Trust and Adviser
    12/14/2023
    600
    $41.5908
    Open market sale
    $41.555 to $41.605
    Trust and Adviser
    01/02/2024
    180,500
    $40.2103
    Open market sale
    $40.00 to $40.995
    Trust and Adviser
    01/02/2024
    20,600
    $41.1790
    Open market sale
    $41.00 to $41.335
    Trust and Adviser
     01/03/2024 120,139
    $41.7746
    Open market sale
    $41.535 to $42.11

    The Reporting Persons undertakes to provide, upon request by the SEC staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price.


    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.
     
       
       
     
    /s/ Patrick E. Beans
     
    Patrick E. Beans, as the Special Holdings Direction Adviser
       
       
     
    AMANDLA MK TRUST
       
       
     
    By:
    /s/ Patrick E. Beans
     
    Patrick E. Beans, Trustee

    Dated: January 4, 2024
    Get the next $NRC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NRC Health Announces First Quarter Results

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2025 and other corporate developments. Highlights: Total Recurring Value Contract Value Increases Sequentially Sales Force Expansion Accelerates New Share Repurchase Program Announced Operating Expenses Decline Dividend Declared Overview Michael D. Hays, Chief Executive Officer of NRC Health, commented on the Company's performance and recent developments: "The key milestone this quarter was a second consecutive quarter of sequential increase in total recurring contract value, which remains the leading indicator of revenue growth. This progress reflects the rebuilding of o

      4/28/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • A New Era of Trust: NRC Health's 2025 Experience Perspective Report Reveals Insights to Elevate the Healthcare Experience

      NRC Health unveils its 2025 Experience Perspective Report, highlighting new research and trends shaping the future of healthcare, with a focus on trust, generational shifts, and evolving consumer demands. NRC Health, a recognized leader in healthcare experience management solutions to transform interactions for patients, consumers, and employees alike, released its 2025 Experience Perspective today during a live national webcast. Known for delivering premier market research and data-driven insights, NRC Health's report features key findings and strategic recommendations based on extensive research involving millions of consumers, patients, and other healthcare leaders nationwide. Guided b

      4/10/25 2:01:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation Declares Quarterly Dividend

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, April 11, 2025, to shareholders of record as of the close of business on Friday, March 28, 2025. For more than 40 years, NRC Health (NASDAQ:NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health's commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health's patient-focuse

      3/24/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    SEC Filings

    See more
    • National Research Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

      5/12/25 9:01:47 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-Q filed by National Research Corporation

      10-Q - NATIONAL RESEARCH CORP (0000070487) (Filer)

      5/9/25 10:02:32 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

      4/28/25 5:12:02 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Beans Patrick E bought $33,974 worth of shares (2,500 units at $13.59), increasing direct ownership by 8% to 35,003 units (SEC Form 4)

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      5/13/25 11:30:22 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Bhandari Parul

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      5/9/25 5:11:12 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Director Wheeler Penny Ann

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      5/9/25 5:09:46 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Beans Patrick E bought $33,974 worth of shares (2,500 units at $13.59), increasing direct ownership by 8% to 35,003 units (SEC Form 4)

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      5/13/25 11:30:22 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by National Research Corporation

      SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

      11/13/24 4:05:19 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by National Research Corporation (Amendment)

      SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

      3/8/24 4:05:05 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by National Research Corporation (Amendment)

      SC 13D/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

      3/5/24 4:31:31 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Leadership Updates

    Live Leadership Updates

    See more
    • National Research Corporation Appoints Trent Green as Chief Executive Officer

      National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare improvement, is pleased to announce the appointment of Trent Green as its incoming Chief Executive Officer, effective June 1, 2025. Green will succeed Mike Hays, the company's current CEO, who will transition to the role of Chairman, ensuring a smooth leadership transition while maintaining NRC Health's mission-driven and shareholder-focused approach. Green brings more than 25 years of healthcare leadership experience, most recently serving as CEO of One Medical, San Francisco, CA, and previously as Chief Operating Officer at Legacy Health, Portland, OR. His expertise in care de

      3/4/25 4:01:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Veteran Patient Experience Executive Jennifer Baron Joins NRC Health as Its First Chief Experience Officer

      Baron will align and advance NRC Health's experience solutions platform to solve health care industry challenges and continue effectively innovating and supporting experience improvement for health systems across the nation. NRC Health, a recognized leader providing solutions and data driven insights for improving health care experiences, announced today the appointment of Jennifer Baron as the organization's first chief experience officer. Baron's addition is part of the organization's continued investments in leadership and innovation to align with the evolving healthcare landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/ho

      4/2/24 11:55:00 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • NRC Health Expands Leadership Team to Accelerate Innovation, Meet Growing Demand for Insights and Solutions

      NRC Health, the leading provider of human-centered healthcare solutions and data-driven insights, is elevating its leadership team with the appointment of four executive-officer positions. The strategic move will allow NRC Health to accelerate innovation while continuing to provide exceptional customer experiences to its partners. Four newly created executive leadership roles will guide NRC Health's strategy and success, including: Helen Hrdy, Chief Customer Officer Jason Hahn, Chief Revenue Officer Christophe Louvion, Chief Product Technology Officer Andy Monnich, Chief Corporate Development Officer "Strong leadership is key in driving innovation and meeting the ever-evolv

      2/1/24 10:00:00 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Financials

    Live finance-specific insights

    See more
    • NRC Health Announces First Quarter Results

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2025 and other corporate developments. Highlights: Total Recurring Value Contract Value Increases Sequentially Sales Force Expansion Accelerates New Share Repurchase Program Announced Operating Expenses Decline Dividend Declared Overview Michael D. Hays, Chief Executive Officer of NRC Health, commented on the Company's performance and recent developments: "The key milestone this quarter was a second consecutive quarter of sequential increase in total recurring contract value, which remains the leading indicator of revenue growth. This progress reflects the rebuilding of o

      4/28/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation Declares Quarterly Dividend

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, April 11, 2025, to shareholders of record as of the close of business on Friday, March 28, 2025. For more than 40 years, NRC Health (NASDAQ:NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health's commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health's patient-focuse

      3/24/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation Announces Fourth Quarter Results

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the fourth quarter 2024 and other corporate developments. Financial Results Revenue for the quarter was approximately $36.9 million compared with approximately $38.0 million in the 2023 quarter. Earnings per diluted share were $0.28 compared with $0.36 for the 2023 quarter. At December 31, 2024, the Company's net indebtedness (total borrowing minus cash and cash equivalents) was approximately $58.5 million. Total recurring contract value (TRCV) was approximately $133.2 million at December 31, 2024. Dividends and Stock Repurchases During the quarter, the Company returned approximately $10.1 millio

      1/27/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care